Adult cardiomyocytes are generally regarded as post‐mitotic cells, yet newer kinase inhibitors (imatinib, sunitinib, and others) developed to interrupt proliferation pathways in cancer cells can cause significant heart failure.
A. Why does this happen? (Consider at least two distinct drugs, effects, or cell types involved)
B. Can you imagine beneficial uses for such compounds, despite these drawbacks? Explain.